Navigation Links
Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya
Date:10/7/2010

EAST HANOVER, N.J., Oct. 7 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced the availability of patient support programs for Gilenya™ (fingolimod) 0.5 mg daily, a first-line oral treatment for relapsing forms of multiple sclerosis. Gilenya was approved by the US Food and Drug Administration (FDA) on September 21, 2010.

For people with MS and healthcare professionals seeking information about Gilenya, Novartis offers free programs to learn about educational resources, the availability of free starter product, and the details of our prescription and medical co-pay support program for eligible patients. People can visit www.Gilenya.com or call 877-408-4974 for information about:  

  • The Gilenya Support Program, which offers treatment information, educational resources, assistance scheduling medical assessments and prescription benefits investigation.
  • The option of free starter product once a prescription has been written to help ensure immediate access to treatment during the benefits investigation process.  Free samples are also being provided to physician's offices and are available through the Gilenya Support Program.
  • The Gilenya Prescription Co-Pay Support Program, which will cover a significant portion of prescription out-of-pocket costs for eligible patients with commercial health insurance.*  
  • The Gilenya Medical Co-Pay Support Program, which will reduce the out-of-pocket costs associated with Gilenya initiation for eligible patients who require certain tests before starting treatment.**
  • The Novartis Patient Assistance Program (PAP), which provides access to Gilenya at no cost for eligible patients who have no third-party coverage. This program is open to all US residents without pharmacy coverage whose income is less than 500% of the Federal Poverty Level. In 2009, the Novartis PAP provided free product valued at over $232 million to
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
    4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
    5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
    6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
    7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
    8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
    9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
    10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
    11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
    (Date:8/29/2014)... WEST JORDAN, Utah , Aug. 29, 2014 /PRNewswire/ ... Imaging Solutions, has acquired Polaris Medical Imaging, a leader ... CT scanners. This strategic acquisition allows BC Technical to ... their capabilities, specifically within MR and CT modalities. ... lower cost service," said Mark Alvarez , president ...
    (Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
    Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2
    ... Reportlinker.com announces that a new market research ... Global Medical Laser Systems Industry ... This report analyzes the worldwide markets ... by the following Product Segments: Surgical Lasers, ...
    ... Reportlinker.com announces that a new market research ... Global Microscopes Industry ... report analyzes the worldwide markets for Microscopes ... Segments: Optical Microscopes, Charged Particle Microscopes, and ...
    Cached Medicine Technology:Global Medical Laser Systems Industry 2Global Microscopes Industry 2
    (Date:9/2/2014)... September 02, 2014 The Quantum ... Quantum Innovations, Inc . (QI), it has ... for MU2 Certification with a private IT security laboratory ... , The platform has Meaningful Use 1 certification status ... (7) approved and 15 pending patents. The accrediting organization ...
    (Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an ... his role as a kicking coach, his kicking business, and ... to retired NFL kicker Michael Husted author of HustedKicking.com. , ... is one of the top pro free agent kickers out ... Anthony at our 2014 Pro Camp and I was impressed ...
    (Date:9/2/2014)... 2 September 2014: The fact that mechanical heart valves ... by data from the ROPAC registry presented for the ... session by Professor Jolien W. Roos-Hesselink, co-chair with Professor ... found that 1.4% of pregnant women with a mechanical ... pregnancy. , The Registry Of Pregnancy And Cardiac disease ...
    (Date:9/2/2014)... 02, 2014 “Harmonicas have been ... decade, primarily to help people with COPD or ... three developed systems,” says Dana Keller, PhD, co-inventor ... the goals are much the same – improved ... type of harmonica.” , The three approaches to ...
    (Date:9/2/2014)... 2014 Fast hosting is a great ... compared many professional web hosting suppliers and announced that ... suppliers. , “It is hard to find a ... their competitors on hosting features, uptime, server speed and ... at affordable rates,” a manager of Top10BestSEOHosting.com says. , ...
    Breaking Medicine News(10 mins):Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2
    ... and Manufacturing Plans Approved for Neuradiab(TM) Multi- center ... Clinical Trial ... TSX: ... the development and,commercialization of cancer therapies, today announced that it has received,notification from the ...
    ... June 3 When Brett Waslefsky,s wife,said her job ... a school,teacher, the stresses of the job, as well ... to stay healthy. With this casual,conversation, a new kind ... Employee Vita, a web-based vitamin company,that offers occupation specific ...
    ... childhood pneumococcal conjugate vaccine has been a boon in ... and the medical community must not get complacent, as ... rise, say scientists at a meeting today in Boston. ... the total burden of pneumococcal disease. It targets ...
    ... Cancer is the Number One Cause ... MAF Canine Cancer Campaign Seeking to Treat and Cure Dogs, DENVER, ... http://www.MorrisAnimalFoundation.org, a canine,cancer exclusive of special interest to dog owners ... the number one cause,of death in dogs over the age of two. ...
    ... To shed unwanted pounds,Americans, spend $46 billion ... and dietitians say merely choosing the right nutrient-dense,foods ... inflammation in our,bodies, and feel more energetic. But ... healthy ingredients we,re encouraged to buy. The article, ...
    ... asserts passage would strip illustrators of essential rights ... educational nonprofits, LAWRENCE, Kan., June 3 ... an international organization,representing highly trained professional medical illustrators ... Orphan Works Act,of 2008" (H.R. 5889/S. 2913), pending ...
    Cached Medicine News:Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 2Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 3Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 4Health News:New Vitamin Company Caters to Occupational Health Concerns 2Health News:Despite vaccine, public should not get complacent about pneumococcal disease 2Health News:Canine Cancer Web Exclusive for Dog Owners and Lovers, Presented by Morris Animal Foundation - Features Colorado State and Cornell University Veterinary Cancer Experts 2Health News:Natural Solutions Names 45 Must-Have Foods for Healthy Weight Loss 2Health News:Association of Medical Illustrators Denounces 'Orphan Works' Bills Before Congress 2
    ... CONMED's family of products allows you to ... generators feature proprietary Energy Synchronous Processing Technology. ... current and voltage in all operational modes. ... to sample current and voltage over 450,000 ...
    ... achieves a secure clot, targeted to the ... hemostasis is needed, when control of bleeding ... and cautery, is ineffective or impractical., CROSSEAL* ... of human Biologically Active Component (BAC) and ...
    GluStitch® is indicated for the closure of uncomplicated skin lacerations where there is little or no tissue loss....
    ... pacemaker family offers some ... automatic devices. Featuring the ... advanced technologies ever seen, ... incorporates the exclusive ventricular ...
    Medicine Products: